Opinion

Video

Targeting of HER3: Insights from HERTHENA-Lung01

Author(s):

Mark A. Socinski, MDHelena A. Yu, MD

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

  1. Please discuss the role of HER3 in the development of resistance to EGFR targeted therapies. (Manickavasagar, et al. Lung Cancer Mang, 2021; Engelman, et al. Science, 2007) 
    • Describe the rationale for targeting HER3 in patients with EGFR TKI resistance.
    • What have data shown with treatment strategies using dual targeting of HER3 and EGFR?

  1. Please review the rationale and study design for HERTHENA-Lung01 and discuss emerging study data and its implications on the treatment landscape. (Goto, et al. WCLC 2023. Abstract OA05.03; Johnson, et al. ESMO 2023. Abstract 1319MO)
    • Briefly outline the study design and key endpoints. What are your perceptions around the brain mets data presented at ESMO this past year?
    • What are some key takeaways from safety data?
    • What implications may these findings have on clinical practice?
Related Videos
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
1 KOL is featured in this series.
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
Sandip P. Patel, MD
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
John V. Heymach, MD, PhD
September 10th 2024

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Jacob Sands, MD
September 10th 2024

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Vlad Vitoc, MD, chairman, chief executive officer, MAIA Biotechnology
September 10th 2024

THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC

Luis Raez, MD
September 10th 2024

Proteomics and Prognostics May Serve as Potential Biomarkers Beyond PD-L1 in Lung Cancer